Changeflow GovPing Healthcare & Life Sciences Methods to Decrease Impurities from Recombinant...
Routine Notice Added Final

Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO granted a patent to Hoffmann-La Roche Inc. for a method of reducing impurities in recombinant protein manufacturing. The invention uses synthetic depth filters to remove non-aggregate produce-related impurities from buffered monoclonal antibody solutions. This is a standard patent grant providing intellectual property protection for the biopharmaceutical manufacturing process.

For biopharmaceutical and pharmaceutical companies engaged in monoclonal antibody production, this patent represents a protected method that competitors may need to license or work around in their own manufacturing processes. The patent grants exclusive rights to the specified impurity reduction technique for the life of the patent.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Methods to decrease impurities from recombinant protein manufacturing processes

Grant US12595294B2 Kind: B2 Apr 07, 2026

Assignee

Hoffmann-La Roche Inc.

Inventors

Marc Pompiati, Christoph Feistl

Abstract

The invention relates to a method of reducing the amount of non-aggregate produce-related impurities (NAPRIs) in a buffered solution of monoclonal antibodies (mAbs), involving the use of a synthetic depth filter. The invention may be of use in the purification of monoclonal 5 antibodies.

CPC Classifications

C07K 16/065

Filing Date

2022-07-12

Application No.

17812145

Claims

15

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12595294B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Biopharmaceutical manufacturing Protein purification
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Manufacturing

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!